Brilliant Inspiration Biotherapeutics

Brilliant Inspiration Biotherapeutics is a China-based biotechnology company developing innovative peptide therapeutics, with disclosed programs focused on transforming growth factor beta signaling modulation. The company is listed as the sponsor of a Phase 1 clinical study of inhaled XQ-001 in healthy subjects, supporting development for idiopathic pulmonary fibrosis. Preclinical disclosures also describe BTI615, a synthetic active peptide intended for myelofibrosis through modulation of transforming growth factor beta biology and bone marrow fibrosis. Publicly available information on the company remains limited, but the available evidence indicates an active early-stage biotech organization centered on novel biotherapeutic candidates.